CNS Drugs 2005-01-01

Tolcapone: a review of its use in the management of Parkinson's disease.

Gillian M Keating, Katherine A Lyseng-Williamson

Index: CNS Drugs 19(2) , 165-84, (2005)

Full Text: HTML

Abstract

Tolcapone (Tasmar) is a selective, reversible inhibitor of peripheral and central catechol-O-methyltransferase (COMT). Results of well designed studies indicate that oral tolcapone is an effective adjunct to levodopa plus a peripheral dopa-decarboxylase inhibitor (DDCI) in patients with fluctuating Parkinson's disease. Tolcapone significantly improves levodopa-induced motor fluctuations and significantly reduces levodopa requirements. The drug is generally well tolerated, with the most commonly occurring adverse events being dopaminergic related. Thus, tolcapone is a useful option in patients with fluctuating Parkinson's disease who are receiving levodopa/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.

Related Compounds

Related Articles:

Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity.

2012-10-17

[Toxicol. Lett. 214(2) , 175-81, (2012)]

Telescoping phenomenon in pathological gambling: association with gender and comorbidities.

2012-11-01

[J. Nerv. Ment. Dis. 200(11) , 996-8, (2012)]

Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.

2010-01-01

[Toxicol. Sci. 113(1) , 243-53, (2010)]

Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice.

2012-03-17

[Behav. Brain Res. 228(2) , 351-8, (2012)]

Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development.

2011-10-07

[J. Biol. Chem. 286(40) , 34752-60, (2011)]

More Articles...